Gilead Sciences, Inc.

Gilead Sciences, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Gilead Sciences, Inc. has 1.24B shares outstanding.

As of June 30, 2026, Gilead Sciences, Inc. maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 223.48, indicating elevated leverage, while an interest coverage ratio of 0.26 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Gilead Sciences, Inc. posted a negative return on equity (ROE) of -20.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.17, reflecting losses generated across the asset base. The company generates approximately 1.43M in revenue per employee across its workforce of 17,150.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.29 indicates how many times Gilead Sciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Gilead Sciences, Inc. recorded 1.04B in income tax expense. The company reported a pretax loss of -1.58B and -2.62B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on August 18, 2026, Gilead Sciences, Inc.'s stock has gained approximately 74.70% over the past 52 weeks. The 50-day moving average sits at 68.64, while the 200-day moving average is 71.37.

Over the twelve months ended June 30, 2026, Gilead Sciences, Inc. generated 24.60B in revenue and converted that into -2.62B in net income, yielding earnings per share of -2.09. EBITDA reached 212.46M, while operating income came in at 9.46B.

As of June 30, 2026, Gilead Sciences, Inc. holds 2.57B in cash and equivalents against 21.20B in total debt, resulting in a net debt position of 18.63B. Total book value stands at 9.56B, with working capital of 2.36B providing operational flexibility.

Gilead Sciences, Inc. produced 10.95B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -491.97M in capital expenditures, free cash flow totaled 10.46B - equivalent to 8.42 per share.

Over the twelve months ended June 30, 2026, Gilead Sciences, Inc. posted a gross margin of 79.59, reflecting its pricing power and cost economics. The operating margin of 38.47 and net profit margin of -10.64 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Gilead Sciences, Inc. paid dividends of 2.64 per share. The dividend payout ratio of -125.56 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Gilead Sciences, Inc.'s most recent stock split took place on January 28, 2013 with a 1:2 split ratio.